Modulation of neurotransmitter transporter function underpins the management of a number of neurological conditions, including depression, anxiety, epilepsy, Parkinson’s disease and addiction, and chronic pain (Pramod et al, 2013). Here, SLC6A2 is linked to Parkinson disease.